PortfoliosLab logoPortfoliosLab logo
ANIP vs. SGHC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ANIP vs. SGHC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ANI Pharmaceuticals, Inc. (ANIP) and Super Group (SGHC) Limited (SGHC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ANIP achieves a 1.51% return, which is significantly lower than SGHC's 11.14% return.


ANIP

1D
-1.21%
1M
-2.11%
YTD
1.51%
6M
-1.49%
1Y
29.33%
3Y*
17.42%
5Y*
18.01%
10Y*
4.41%

SGHC

1D
-0.54%
1M
-1.61%
YTD
11.14%
6M
18.57%
1Y
45.60%
3Y*
60.66%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ANIP vs. SGHC - Yearly Performance Comparison


2026 (YTD)2025202420232022
ANIP
ANI Pharmaceuticals, Inc.
1.51%42.80%0.25%37.06%2.21%
SGHC
Super Group (SGHC) Limited
11.14%95.00%107.65%5.67%-63.64%

Correlation

The correlation between ANIP and SGHC is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.14

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (All Time)
Calculated using the full available price history since Jan 31, 2022

0.25

The correlation between ANIP and SGHC shifts across timeframes, from 0.14 (1 year) to 0.25 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ANIP:

$1.73B

SGHC:

$6.51B

EPS

ANIP:

$4.26

SGHC:

$0.40

PE Ratio

ANIP:

18.81

SGHC:

31.91

PEG Ratio

ANIP:

0.13

SGHC:

1.35

PS Ratio

ANIP:

1.83

SGHC:

3.03

PB Ratio

ANIP:

3.07

SGHC:

9.53

Total Revenue (TTM)

ANIP:

$923.71M

SGHC:

$2.15B

Gross Profit (TTM)

ANIP:

$486.11M

SGHC:

$617.43M

EBITDA (TTM)

ANIP:

$234.71M

SGHC:

$394.23M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANIP vs. SGHC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANIP
ANIP Risk / Return Rank: 6565
Overall Rank
ANIP Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
ANIP Sortino Ratio Rank: 6969
Sortino Ratio Rank
ANIP Omega Ratio Rank: 6565
Omega Ratio Rank
ANIP Calmar Ratio Rank: 6363
Calmar Ratio Rank
ANIP Martin Ratio Rank: 6161
Martin Ratio Rank

SGHC
SGHC Risk / Return Rank: 6969
Overall Rank
SGHC Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
SGHC Sortino Ratio Rank: 7070
Sortino Ratio Rank
SGHC Omega Ratio Rank: 6767
Omega Ratio Rank
SGHC Calmar Ratio Rank: 6666
Calmar Ratio Rank
SGHC Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANIP vs. SGHC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and Super Group (SGHC) Limited (SGHC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ANIPSGHCDifference
Sharpe ratioReturn per unit of total volatility

-0.17

Sortino ratioReturn per unit of downside risk

-0.07

Omega ratioGain probability vs. loss probability

1.18

1.20

-0.02

Calmar ratioReturn relative to maximum drawdown

1.03

1.22

-0.19

Martin ratioReturn relative to average drawdown

1.94

2.79

-0.85

ANIP vs. SGHC - Sharpe Ratio Comparison

The current ANIP Sharpe Ratio is 0.83, which is comparable to the SGHC Sharpe Ratio of 1.00. The chart below compares the historical Sharpe Ratios of ANIP and SGHC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ANIPSGHCDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.83

1.00

-0.17

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.39

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.05

0.23

-0.27

Drawdowns

ANIP vs. SGHC - Drawdown Comparison

The maximum ANIP drawdown since its inception was -98.81%, which is greater than SGHC's maximum drawdown of -76.02%. Use the drawdown chart below to compare losses from any high point for ANIP and SGHC.


Loading charts...

Drawdown Indicators


ANIPSGHCDifference

Max Drawdown

Largest peak-to-trough decline

-98.81%

-76.02%

-22.79%

Max Drawdown (1Y)

Largest decline over 1 year

-28.66%

-37.67%

+9.01%

Max Drawdown (3Y)

Largest decline over 3 years

-28.66%

-37.67%

+9.01%

Max Drawdown (5Y)

Largest decline over 5 years

-59.38%

Max Drawdown (10Y)

Largest decline over 10 years

-72.96%

Current Drawdown

Current decline from peak

-82.19%

-7.21%

-74.98%

Average Drawdown

Average peak-to-trough decline

-79.40%

-45.71%

-33.69%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.18%

16.39%

-1.21%

Volatility

ANIP vs. SGHC - Volatility Comparison

ANI Pharmaceuticals, Inc. (ANIP) and Super Group (SGHC) Limited (SGHC) have volatilities of 10.33% and 9.95%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ANIPSGHCDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.33%

9.95%

+0.38%

Volatility (6M)

Calculated over the trailing 6-month period

24.37%

30.57%

-6.20%

Volatility (1Y)

Calculated over the trailing 1-year period

35.66%

46.12%

-10.46%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

46.31%

59.53%

-13.22%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.29%

59.53%

-11.24%

Dividends

ANIP vs. SGHC - Dividend Comparison

ANIP has not paid dividends to shareholders, while SGHC's dividend yield for the trailing twelve months is around 3.26%.


PositionTTM20252024
ANIP
ANI Pharmaceuticals, Inc.
0.00%0.00%0.00%
SGHC
Super Group (SGHC) Limited
3.26%1.34%4.01%

Financials

ANIP vs. SGHC - Financials Comparison

This section allows you to compare key financial metrics between ANI Pharmaceuticals, Inc. and Super Group (SGHC) Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M600.00M20222023202420252026
237.46M
578.00M
(ANIP) Total Revenue
(SGHC) Total Revenue
Values in USD except per share items

ANIP vs. SGHC - Profitability Comparison

The chart below illustrates the profitability comparison between ANI Pharmaceuticals, Inc. and Super Group (SGHC) Limited over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
24.2%
Portfolio components
ANIP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 237.46M. Therefore, the gross margin over that period was 0.0%.

SGHC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Super Group (SGHC) Limited reported a gross profit of 140.00M and revenue of 578.00M. Therefore, the gross margin over that period was 24.2%.

ANIP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported an operating income of 38.89M and revenue of 237.46M, resulting in an operating margin of 16.4%.

SGHC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Super Group (SGHC) Limited reported an operating income of 100.00M and revenue of 578.00M, resulting in an operating margin of 17.3%.

ANIP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a net income of 29.49M and revenue of 237.46M, resulting in a net margin of 12.4%.

SGHC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Super Group (SGHC) Limited reported a net income of 67.00M and revenue of 578.00M, resulting in a net margin of 11.6%.


Frequently Asked Questions


ANIP and SGHC have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ANIP has higher volatility (10.33%) compared to SGHC (9.95%). In terms of maximum drawdown, ANIP dropped -98.81% vs SGHC's -76.02%.

SGHC currently has the higher Sharpe Ratio (1.00 vs 0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ANIP and SGHC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer